Protective effect of HDL on endothelial NO production: the role of DDAH/ADMA pathway.
Accumulating studies have demonstrated that the dimethylarginine dimethylaminohydrolase/asymmetric dimethylarginine (DDAH/ADMA) system is a novel pathway for modulating nitric oxide (NO) production. The aim of this study was to investigate whether the protective effect of high density lipoprotein (HDL) on endothelial NO production was related to its effect on DDAH/ADMA pathway. Human umbilical vein endothelial cells (HUVECs) were prior exposed to HDL (10, 50, or 100 μg/ml) for 1 h, and then incubated with oxidized low density lipoprotein (ox-LDL) (100 μg/ml) for 24 h. The cultured medium was collected for measuring the concentration of NO and ADMA. The cells were collected for measuring the mRNA and protein expression of DDAH-II as well as DDAH activity. HUVECs treated with ox-LDL (100 μg/ml) for 24 h significantly decreased the concentration of NO, the mRNA and protein expression of DDAH-II as well as DDAH activity and increased the level of ADMA. Pretreatment with HDL (10, 50, or 100 μg/ml) could counteract these changes induced by ox-LDL (100 μg/ml). HDL significantly increased the attenuated endothelial cell NO production induced by ox-LDL, which was attributed to its effect on DDAH/ADMA pathway.
Department of Cardiology, Second Xiangya Hospital, Central South University, Middle Ren-Min Road 139, Changsha 410011, China.
Zhen-Yu
ZY
Peng
Shui-Ping
SP
Zhao
Bai-Mei
BM
He
Dao-Quan
DQ
Peng
Min
M
Hu
D000581:Amidohydrolases / Q000502:physiology*; D001120:Arginine / Q000031:analogs & derivatives* / Q000502:physiology; D001483:Base Sequence; D015153:Blotting, Western; D002478:Cells, Cultured; D017931:DNA Primers; D004730:Endothelium, Vascular / Q000378:metabolism*; D006801:Humans; D008075:Lipoproteins, HDL / Q000502:physiology*; D009569:Nitric Oxide / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D017931:DNA Primers; D008075:Lipoproteins, HDL; C487735:dimethylarginine; D009569:Nitric Oxide; D001120:Arginine; D000581:Amidohydrolases; C059999:dimethylargininase
Pharmacol Res. 2007 Dec;56(6):515-21
17977009
Eur J Clin Pharmacol. 2006 Mar;62(3):179-84
16447050
Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):943-9
19359663
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3227-45
17933965
JAMA. 2007 Aug 15;298(7):786-98
17699012
Circulation. 1998 Nov 3;98(18):1842-7
9799202
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3013-20
9409288
Circulation. 2002 Aug 20;106(8):987-92
12186805
J Cell Sci. 2004 May 15;117(Pt 12):2427-9
15159447
Am J Cardiol. 2002 Sep 15;90(6):648-50
12231097
Biochem Biophys Res Commun. 2006 Oct 20;349(2):683-93
16959216
Circulation. 1994 Jun;89(6):2525-32
8205660
Biochem J. 1999 Oct 1;343 Pt 1:209-14
10493931
Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):1816-22
15308550
Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32
15198963
Circ Res. 2007 Sep 14;101(6):627-35
17673667
Diabetes Res Clin Pract. 2009 Nov;86(2):e37-8
19766342
Med Sci Monit. 2009 Sep;15(9):BR248-53
19721392
Circ Res. 2007 Jul 20;101(2):e2-10
17601800
J Chromatogr B Biomed Sci Appl. 1997 May 9;692(2):467-71
9188838
Clin J Am Soc Nephrol. 2009 Jun;4(6):1115-20
19389824
Cell Adh Migr. 2008 Jul-Sep;2(3):149-50
19270535
Circulation. 2001 Aug 7;104(6):700-4
11489778
Curr Opin Cardiol. 2008 Jul;23(4):370-8
18520722
J Biol Chem. 2003 Mar 14;278(11):9142-9
12511559
Circulation. 2009 Mar 31;119(12):1592-600
19289633
J Clin Invest. 2004 Feb;113(4):569-81
14966566
Clin Chem Lab Med. 2003 Nov;41(11):1467-72
14656027
Circulation. 2007 Mar 13;115(10):1285-95
17353456
Curr Med Res Opin. 2004 Aug;20(8):1253-68
15324528
Atherosclerosis. 2010 Mar;209(1):66-73
19775692
Diabetes Metab Res Rev. 2009 Mar;25(3):242-9
19229883
Hypertension. 2008 Mar;51(3):696-703
18250362
Int J Cardiol. 2008 Aug 1;128(1):42-7
17643522
Am J Physiol. 1995 Jun;268(6 Pt 2):H2224-31
7541959